AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026 AC Immune (NASDAQ: ACIU) presented Phase 1 data March 19, 2026 showing the first in vivo PET images of TDP-43 brain pathology using tracer ACI-19626. Initial scans showed significantly higher tracer uptake in key cortical and subcortical regions of C9orf72 genetic FTD patients versus healthy subjects.ACI-19626 demonstrated good safety, acceptable dosimetry, and a PK profile with rapid brain uptake and washout. Part 1 final data expected H1 2026; Part 2 expansion is underway to study additional patient populations including ALS and LATE.

#ACIU AC Immune Presents First In vivo Images of Brain TDP-43 Pathology from Phase 1 Trial of PET tracer ACI-19626, at AD/PDTM 2026

www.stocktitan.net/news/ACIU/ac-immune-pres...

AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update AC Immune (NASDAQ: ACIU) reported full-year 2025 results and a corporate update. Key items: interim Phase 2 VacSYn data suggest ACI-7104 may slow Parkinson’s progression and showed 100% immunogenic responder rate. Cash was CHF 91.4M at Dec 31, 2025, extending runway to Q3 2027. The company reported a net loss of CHF 70.5M and expects 2026 cash expenditure of CHF 55–65M. Management reduced workforce by ~30% and advanced ACI-19764 into Phase 1.

#ACIU AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ACIU/ac-immune-repo...

AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026 AC Immune (NASDAQ: ACIU) will host an industry symposium on Parkinson’s disease and present a first-in-class TDP-43 PET-tracer at AD/PD™ 2026 in Copenhagen, March 17–21, 2026. The symposium on March 18 highlights a precision prevention approach and features data updates, scientific talks, and a Q&A session.Oral presentation of [18F]ACI-19626 is scheduled for March 19, focusing on biomarker pathways linking amyloid, tau, and neurodegeneration. A symposium replay will be available on the company events page.

#ACIU AC Immune Announces Upcoming Industry Symposium on Parkinson’s Disease and Presentation at AD/PD™ 2026

www.stocktitan.net/news/ACIU/ac-immune-anno...

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#PEW, #FNF, #MTH, #ACIU, #BVN

#OptionFlow #OptionsTrading #Trading

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #PEW 9.2x
2. #FNF 3.6x
3. #MTH 3.2x
4. #ACIU 2.8x
5. #BVN 2.4x

#OptionFlow #OptionsTrading #Trading

Most Searched, Thursday December 11, 2025 – Crystal Equity Research

Most searched small-cap stocks, Thu Dec 11th - #OCG #AXIL #JBLU #RR #TE #DNN #ACIU #MIGI #IRBT #ONDS #NXDR #PLUG #EXK #RZLT #USAR #TGB #NAK #MAIA #DOMH #BKKT - More: crystalequityresearch.com/most-searche... - #smallcap

#ACIU AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

www.stocktitan.net/news/ACIU/ac-immune-posi...

Feira da Mulher Empreendedora será realizada neste domingo com espaço de negócios e lazer em Urussanga A Feira da Mulher Empreendedora será realizada neste domingo, dia 9, em Urussanga, com a participação de mais 50 expositoras que transformaram o sonho de empreender em realidade. O evento acontece a partir das 10 horas, na Praça de Itália do Parque Municipal, com a comercialização de produtos e serviços por meio do “Mesa e […]

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update AC Immune (NASDAQ: ACIU) reported Q3 2025 results and a corporate update on November 4, 2025. The company holds CHF 108.5 million in cash resources as of September 30, 2025 (CHF 27.7M cash and CHF 80.7M short-term assets) and said this provides funding to the end of Q3 2027 excluding milestone income. Management narrowed investment focus to three Phase 2 active immunotherapies and small-molecule programs (NLRP3, Tau, a-syn), reduced workforce by ~30%, and recognized CHF 0.5M restructuring expenses.Near-term milestones expected in Q4 2025 include IND/CTA filing for ACI-19764, lead declarations and IND-enabling starts for Morphomer programs, and multiple Phase 1/2 readouts and interim Part 1 VacSYn results.

#ACIU AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ACIU/ac-immune-repo...

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine Aggregated TDP-43 is a pathological hallmark of neurodegenerative diseases including ALS, FTD and LATE, and a co-pathology in Alzheimer’s and Parkinson’s

#ACIU First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune’s ACI-19626 in Precision Medicine

www.stocktitan.net/news/ACIU/first-characte...

Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine AC Immune (NASDAQ: ACIU) announced the peer-reviewed publication of Phase 1b/2a trial results for its anti-pTau active immunotherapy in eBioMedicine. The study compared two formulations: ACI-35.030 and JACI-35.054 in early Alzheimer's disease patients.Key findings showed that ACI-35.030, developed using AC Immune's SupraAntigen® technology, demonstrated superior performance by generating rapid and potent polyclonal response against pathological Tau forms after a single dose. The treatment maintained 94-100% response rates through week 74 in high-dose cohorts, with no clinically relevant safety concerns.Based on these positive results, ACI-35.030 has advanced to a potentially registration-enabling Phase 2b ReTain clinical trial in preclinical Alzheimer's disease, becoming the first active immunotherapy targeting Tau to be investigated in approximately 500 participants.

#ACIU Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine

www.stocktitan.net/news/ACIU/peer-reviewed-...

(NASDAQ: #ACIU)
#ACImmune trims 30% of its workforce and sharpens its pipeline focus, extending its cash runway through Q3 2027. A strategic reset aiming for efficiency and long-term sustainability.
prismmarketview.com/ac-immune-re...

AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway AC Immune (NASDAQ: ACIU) has announced a strategic restructuring to optimize its pipeline focus and extend its cash runway. The company will implement a 30% workforce reduction while concentrating on its three clinical-stage active immunotherapy programs and key small molecule programs targeting NLRP3 and Tau.The restructuring will extend the company's cash runway through Q3 2027, supported by current cash resources of CHF 127.1 million as of June 30, 2025. The company maintains its clinical timeline guidance, with interim data expected from ACI-7104.056 in H2 2025 and ACI-24.060 in H1 2026.The implementation will be completed by the end of 2025, with cost reductions becoming fully effective in early 2026. Affected employees will receive severance packages and support for new employment opportunities.

#ACIU AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway

www.stocktitan.net/news/ACIU/ac-immune-shar...

AC Immune Reports Breakthrough: 20-Fold Antibody Increase in Parkinson's Treatment, Plus $157M Cash Runway Q2 results reveal strong immunotherapy data across 3 Phase 2 trials. CHF 127.1M cash extends runway to 2027. Multiple catalysts ahead - see full pipeline updates.

#ACIU AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ACIU/ac-immune-repo...

AC Immune Q1 Results: Breakthrough in Parkinson's Treatment Shows Promise, Cash Runway Extended to 2027 New clinical data reveals promising results for Parkinson's treatment. Strong financial position with CHF 146M cash extends runway to 2027. See complete pipeline updates.

#ACIU AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ACIU/ac-immune-repo...

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease AC Immune (NASDAQ: ACIU) has reported positive interim results from its Phase 2 VacSYn clinical trial of ACI-7104.056, an active immunotherapy for early Parkinson's disease. The treatment has demonstrated significant efficacy, producing anti-α-synuclein antibody levels over 20-fold higher than placebo after 4 immunizations.The trial's Part 1 involves over 30 patients randomized at a 3:1 ratio (treatment:placebo). Key findings show that antibody responses were effectively induced at week 6 after 2 immunizations and were further enhanced with additional doses. The treatment has shown a favorable safety profile with no serious adverse events reported, with only mild side effects including injection site reactions and headaches.Based on upcoming interim results in 2025, including pharmacodynamic and biomarker data, the company may proceed with Part 2 of the trial, expanding to up to 150 patients. This phase will evaluate disease progression through motor and non-motor symptoms, along with digital, imaging, and fluid biomarkers.

#ACIU AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

www.stocktitan.net/news/ACIU/ac-immune-repo...

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update AC Immune (NASDAQ: ACIU) reported its full year 2024 financial results, highlighting a landmark deal with Takeda worth $100 million upfront and potential milestones up to $2.1 billion plus royalties for ACI-24.060. The company received a CHF 24.6 million milestone payment from Janssen for enrollment progress in the JNJ-2056 Phase 2b trial.Key financial metrics include:Cash position of CHF 165.5 million, providing funding into Q1 2027Contract revenues of CHF 27.3 million in 2024R&D expenses increased to CHF 62.6 millionNet loss of CHF 50.9 millionClinical progress includes positive interim safety data for ACI-24.060 in Down syndrome patients and encouraging results for ACI-7104.056 in Parkinson's disease. The company expects 2025 total cash expenditure between CHF 75-85 million.

#ACIU AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

www.stocktitan.net/news/ACIU/ac-immune-repo...

AC Immune's Down Syndrome Alzheimer's Drug Shows Promising Safety Data in Clinical Trial AC Immune reports positive interim safety results for ACI-24.060 in Down syndrome patients, with no serious adverse events after one year of treatment. Trial advances to final phase.

#ACIU AC Immune Reports Interim Safety Data from Phase 1b/2 ABATE Trial of ACI-24.060 in Down syndrome

#news #StockMarket #stocks

www.stocktitan.net/news/ACIU/ac-immune-repo...

Just In: ( NASDAQ: #ACIU ) AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

#StockMarket #News

#ACIU AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease

www.stocktitan.net/news/ACIU/ac-immune-repo...

JUST IN: ( NASDAQ: #ACIU ) AC Immune Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

#StockMarket #News

BREAKING NEWS: ( NASDAQ: #ACIU ) AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's Disease

#StockMarket #News

Just In: ( NASDAQ: #ACIU ) AC Immune's PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions

#StockMarket #News

Breaking News: ( NASDAQ: #ACIU ) AC Immune's ACI-35.030 (now "JNJ-2056") Granted FDA Fast Track Designation for Alzheimer's Disease

#StockMarket #News